Back to News
Market Impact: 0.28
Humacyte's Symvess Shelf Life Extended To 36 Months Following FDA Authorization
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Humacyte said the FDA authorized extending Symvess's refrigerated shelf life to 36 months from 18 months. The doubling of the expiration period could improve inventory management, distribution flexibility, and commercial usability for the tissue-engineered vessel.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
HUMA0.62
More News
- Pharvaris at Wells Fargo conference: oral HAE drug gains ground
- Samsung works to draw iPhone users to its foldables even as Apple enters the market
- Oil Tops $100 on Supply Fears, Apple Faces a Big Test
- Nano-X Imaging (NNOX) Q2 2026 Earnings Call Transcript
- Chewy (CHWY) Q2 2026 Earnings Call Transcript
- Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Contact the Firm to Learn About Their Legal Rights